Abstract
In a previous dose escalation study our group found that combining 90μg/kg rFVIIa with HBOC-201 reduced blood loss and improved physiologic parameters compared to HBOC alone. In this follow-up study in a swine liver injury model, we found that while there were no adverse hematology effects and trends observed in the previous study were confirmed, statistical significance could not be reached. Additional pre-clinical studies are indicated to identify optimal components of a multifunctional blood substitute for clinical use in trauma.
Publication types
-
Comparative Study
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Blood Substitutes / pharmacology
-
Blood Volume / drug effects
-
Drug Interactions
-
Factor VIIa / pharmacology*
-
Factor VIIa / therapeutic use
-
Female
-
Fluid Therapy / methods*
-
Hemoglobins / pharmacology*
-
Hemoglobins / therapeutic use
-
Hospitals*
-
Male
-
Oxygen / metabolism
-
Recombinant Proteins / pharmacology*
-
Recombinant Proteins / therapeutic use
-
Shock, Hemorrhagic / drug therapy*
-
Shock, Hemorrhagic / metabolism
-
Shock, Hemorrhagic / pathology
-
Shock, Hemorrhagic / physiopathology
-
Survival Analysis
-
Swine*
Substances
-
Blood Substitutes
-
Hemoglobins
-
Recombinant Proteins
-
HBOC 201
-
Factor VIIa
-
Oxygen